Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.

NCT01591421 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT01591421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01591421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 1/2
Overall status
Completed
Start date
September 6, 2012
Completion date
November 12, 2019
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer